Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lukas K van Vugt

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Nederlands Tijdschrift Voor Geneeskunde|April 29, 2021
[Acute kidney injury, an avoidable problem]Lukas K van Vugt, Eva Wagenaar, Ronald W van Etten
Pharmacogenomics|June 28, 2022
Personalized anti-rejection therapy with alemtuzumab for kidney transplant recipientsDennis A Hesselink, Daphne M Hullegie-Peelen, Lukas K van Vugt
British Journal of Clinical Pharmacology|June 18, 2024
Challenges for the improvement of valganciclovir prophylaxis in solid organ transplantation and the possible role of therapeutic drug monitoring in adultsLukas K van Vugt, Dennis A Hesselink, Brenda C M de Winter
Therapeutic Drug Monitoring|July 21, 2025
A Real-World Clinical Evaluation of Ganciclovir Exposure and Cytomegalovirus Viremia Outcomes After Adult Kidney TransplantationLukas K van Vugt, Rawan Saleh, Dennis A Hesselink, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|July 15, 2024
Recurrent treatment of refractory acute cellular rejection with alemtuzumab after lung transplantationEva van Haren, Lukas K van Vugt, Nynke Wijbenga, et al.
Expert Opinion on Investigational Drugs|September 29, 2022
Investigational drugs for the treatment of kidney transplant rejectionLukas K van Vugt, Maaike R Schagen, Annelies de Weerd, et al.
Clinical Pharmacology and Therapeutics|May 15, 2025
Alemtuzumab Exposure and T Lymphocyte Depletion: A Population Pharmacokinetic-Pharmacodynamic Model of Alemtuzumab Induction Therapy for Kidney TransplantationLukas K van Vugt, Tom C Zwart, Suzanne Bezstarosti, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|November 29, 2023
A Decade of Experience With Alemtuzumab Therapy for Severe or Glucocorticoid-Resistant Kidney Transplant RejectionLukas K van Vugt, Marieke van der Zwan, Marian C Clahsen-van Groningen, et al.
Clinical Transplantation|December 5, 2024
Multicenter, Real-World Clinical Evaluation of Alemtuzumab and Anti-Thymocyte Globulin for Severe Acute T Cell-Mediated Kidney Transplant RejectionLukas K van Vugt, Erzsi Tegzess, Marieke van der Zwan, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Nederlands Tijdschrift Voor Geneeskunde|April 29, 2021
[Acute kidney injury, an avoidable problem]Lukas K van Vugt, Eva Wagenaar, Ronald W van Etten
Pharmacogenomics|June 28, 2022
Personalized anti-rejection therapy with alemtuzumab for kidney transplant recipientsDennis A Hesselink, Daphne M Hullegie-Peelen, Lukas K van Vugt
British Journal of Clinical Pharmacology|June 18, 2024
Challenges for the improvement of valganciclovir prophylaxis in solid organ transplantation and the possible role of therapeutic drug monitoring in adultsLukas K van Vugt, Dennis A Hesselink, Brenda C M de Winter
Therapeutic Drug Monitoring|July 21, 2025
A Real-World Clinical Evaluation of Ganciclovir Exposure and Cytomegalovirus Viremia Outcomes After Adult Kidney TransplantationLukas K van Vugt, Rawan Saleh, Dennis A Hesselink, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|July 15, 2024
Recurrent treatment of refractory acute cellular rejection with alemtuzumab after lung transplantationEva van Haren, Lukas K van Vugt, Nynke Wijbenga, et al.
Expert Opinion on Investigational Drugs|September 29, 2022
Investigational drugs for the treatment of kidney transplant rejectionLukas K van Vugt, Maaike R Schagen, Annelies de Weerd, et al.
Clinical Pharmacology and Therapeutics|May 15, 2025
Alemtuzumab Exposure and T Lymphocyte Depletion: A Population Pharmacokinetic-Pharmacodynamic Model of Alemtuzumab Induction Therapy for Kidney TransplantationLukas K van Vugt, Tom C Zwart, Suzanne Bezstarosti, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|November 29, 2023
A Decade of Experience With Alemtuzumab Therapy for Severe or Glucocorticoid-Resistant Kidney Transplant RejectionLukas K van Vugt, Marieke van der Zwan, Marian C Clahsen-van Groningen, et al.
Clinical Transplantation|December 5, 2024
Multicenter, Real-World Clinical Evaluation of Alemtuzumab and Anti-Thymocyte Globulin for Severe Acute T Cell-Mediated Kidney Transplant RejectionLukas K van Vugt, Erzsi Tegzess, Marieke van der Zwan, et al.
Pageof 1